General Session 2 (available abstracts)
Publication Number: GS2-04
Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
Rosie Bradley, Jeremy Braybrooke, Richard Gray1, et al.
AI instead of tamoxifen reduces the risk of breast cancer recurrence by about 20 percent in premenopausal women with ovarian suppression. The authors conclude: "If the surprising lack of benefit in N4 + disease is an incidental finding, then the absolute benefit is greater for women with a higher absolute risk of recurrence."
Publication Number: GS2-06
Jeremy Braybrooke, Rosie Bradley, Richard Gray, et al.
Anthracycline in addition to taxane chemotherapy reduced the risk of breast cancer recurrence by 18 percent compared to Taxane Mono.
Publication Number: GS2-07
Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Kevin M Kalinsky, William E Barlow, Julie R Gralow, et al.
Premenopausal patients with 1-3 + LN and RS <25 demonstrated a statistically significant improvement in DRFI with additional CT. A small proportion of the S1007 premenopausal participants underwent ovarian function suppression.